Investigational drug · Phase 2
LTG-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Pain, Postoperative.
Phase 2Last checked: Nov 19, 2026Latest source record: May 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "LTG-001"
First trial start
2024
Dec 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LTG-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Pain, Postoperative
Approved drugs for the same conditions: Acute pain · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "LTG-001" as an intervention, largest first.
- An Efficacy and Safety Study of LTG-001 Following AbdominoplastyPivotal-lookingCompleted
Latigo BiotherapeuticsIndustry
NCT07102459 · 343 participants · Start Jul 24, 2025 · Primary completion Jan 7, 2026
Drug: Experimental: LTG-001 High Dose; Experimental: LTG-001 Low Dose and 2 more · For: Acute Pain; Postoperative Pain Control
Sites: Phoenix, Arizona; Atlanta, Georgia; Houston, Texas · 5 sites in all
- This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third MolarsPivotal-lookingCompleted
Latigo BiotherapeuticsIndustry
NCT06774625 · 250 participants · Start Dec 19, 2024 · Primary completion Aug 8, 2025
Drug: LTG-001 High Dose; LTG-001 Mid Dose and 2 more · For: Acute Pain, Postoperative
Sites: Salt Lake City, Utah
- A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy ParticipantsPivotal-lookingActive, not recruiting
Latigo BiotherapeuticsIndustry
NCT06049095 · 204 participants (planned) · Start Oct 17, 2023 · Primary completion Sep 2026
Drug: LTG-001; Placebo · For: Healthy
Sites: Christchurch, New Zealand
Latigo BiotherapeuticsIndustry
NCT07341152 · 14 participants · Start Oct 6, 2025 · Primary completion Nov 17, 2025
Drug: LTG-001 SDD; LTG-001 Formulation A Prototype 1 and 2 more · For: Pain Management
Sites: Miami, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Phase 2b Trial of a NaV1.8 Inhibitor for Acute Pain.
Singla N, Katz NP, Vaughn B, et al. · N Engl J Med 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.